LONG-TERM RELAPSE-FREE SURVIVAL IN ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA

Authors:
  • RGRD GINGRICH
    RD GINGRICH
  • CBCP BURNS
    CP BURNS
  • JAJO ARMITAGE
    JO ARMITAGE
  • SASB AUNAN
    SB AUNAN
  • RERW EDWARDS
    RW EDWARDS
  • FDFR DICK
    FR DICK
  • LMLC MAGUIRE
    LC MAGUIRE
  • JLJT LEIMERT
    JT LEIMERT

  • 1 January 1985
    • journal article
    • research article
    • Vol. 69  (2) , 153-160
    • PMID:3855697
Abstract
An intensive treatment program with curative intent was designed for adults with acute lymphoblastic leukemia (ALL). Forty-eight consecutive patients were treated with this protocol and 39 (81%) obtained a complete remission. Although the complete remission rate was high for patients with both null-cell and T-cell disease, those with null-cell leukemia had a significantly greater median duration of remission (> 306 wk) than patients with T-cell disease (62 wk). The median survival by life-table analysis for the 48 patients is projected to be > 310 wk and 5 patients have finished the 3-yr treatment program and have been off therapy for 1-3 yr without recurrence of disease. Classification of adult ALL by immune marker status is an important and easily done pretherapy maneuver that identifies subsets of patients with a significantly different prognosis when treated with the protocol described in this study. Those patients for whom leukemic cells had T-cell characteristics had a short median duration of remission. This treatment protocol identifies, by therapeutic response, a subset of adult patients with ALL whose leukemic blasts are characterized by the absence of immunological markers and appear, in substantial proportion, to be potentially curable.